<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702026</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 08-1-031</org_study_id>
    <nct_id>NCT00702026</nct_id>
  </id_info>
  <brief_title>The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients</brief_title>
  <official_title>The Effect of a Multispecies Probiotic on Hypersensitivity in IBS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winclove Bio Industries BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a specifically designed multispecies&#xD;
      probiotic decreases visceral hypersensitivity in IBS-patient (defined by an increased pain&#xD;
      tolerance threshold). Moreover, the effect on general symptom scores and inflammatory and&#xD;
      microbiological parameters will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain tolerance threshold</measure>
    <time_frame>t=0 and t=6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS score for pain at pressure step 29 mmHg</measure>
    <time_frame>t=0 and t=6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>multispecies probiotic (Ecologic 801)</intervention_name>
    <description>once daily, 5 gram [10e9 cfu/gram]</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ecologic 801</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily, 5 gram [10e9 cfu/gram]</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of IBS according to the Rome III criteria&#xD;
&#xD;
          -  Increased visceral perception according to barostat measurements, defined as a pain&#xD;
             tolerance threshold at smaller than or equal to 23 mmHg&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  BMI between 18.5 and 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known gastro-intestinal diseases&#xD;
&#xD;
          -  Major abdominal surgery&#xD;
&#xD;
          -  Previous radiotherapy, chemotherapy&#xD;
&#xD;
          -  Clinical significant systemic diseases&#xD;
&#xD;
          -  Critically ill patients or patients suffering from severe acute pancreatitis&#xD;
&#xD;
          -  Patients with organs failure&#xD;
&#xD;
          -  Patients receiving enteral feeding&#xD;
&#xD;
          -  Excessive alcohol intake (greater than 15 consumptions per week)&#xD;
&#xD;
          -  (planned) pregnancy or lactation&#xD;
&#xD;
          -  Use of pre-, probiotics in the month before and during the study&#xD;
&#xD;
          -  Use of antibiotics in the two months before and during the study&#xD;
&#xD;
          -  Use of anti-diarrhoea medication, anti-laxatives or anti-acid medication in the two&#xD;
             weeks before and during the study&#xD;
&#xD;
          -  Use of anti depressives (especially SSRI's) in the month before and during the study&#xD;
&#xD;
          -  Use of other medication if less then one month on stable dosage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A AM Masclee, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Multispecies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

